全文获取类型
收费全文 | 55篇 |
免费 | 11篇 |
专业分类
儿科学 | 27篇 |
基础医学 | 2篇 |
临床医学 | 2篇 |
内科学 | 6篇 |
特种医学 | 1篇 |
肿瘤学 | 28篇 |
出版年
2024年 | 1篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 6篇 |
2017年 | 4篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 1篇 |
2013年 | 4篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 1篇 |
2008年 | 2篇 |
2007年 | 3篇 |
2005年 | 4篇 |
2004年 | 1篇 |
2003年 | 4篇 |
2002年 | 1篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 2篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
排序方式: 共有66条查询结果,搜索用时 15 毫秒
61.
I M Ambros J Benard M Boavida N Bown H Caron V Combaret J Couturier C Darnfors O Delattre J Freeman-Edward C Gambini N Gross C M Hattinger A Luegmayr J Lunec T Martinsson K Mazzocco S Navarro R Noguera S O'Neill U Potschger S Rumpler F Speleman G P Tonini A Valent N Van Roy G Amann B De Bernardi P Kogner R Ladenstein J Michon A D J Pearson P F Ambros 《Journal of clinical oncology》2003,21(11):2077-2084
PURPOSE: Therapy stratification based on genetic markers is becoming increasingly important, which makes commitment to the highest possible reliability of the involved markers mandatory. In neuroblastic tumors, amplification of the MYCN gene is an unequivocal marker that indicates aggressive tumor behavior and is consequently used for therapy stratification. To guarantee reliable and standardized quality of genetic features, a quality-assessment study was initiated by the European Neuroblastoma Quality Assessment (ENQUA; connected to International Society of Pediatric Oncology) Group. Materials and METHODS: One hundred thirty-seven coded specimens from 17 tumors were analyzed in 11 European national/regional reference laboratories using molecular techniques, in situ hybridization, and flow and image cytometry. Tumor samples with divergent results were re-evaluated. RESULTS: Three hundred fifty-two investigations were performed, which resulted in 23 divergent findings, 17 of which were judged as errors after re-evaluation. MYCN analyses determined by Southern blot and in situ hybridization led to 3.7% and 4% of errors, respectively. Tumor cell content was not indicated in 32% of the samples, and 11% of seemingly correct MYCN results were based on the investigation of normal cells (eg, Schwann cells). Thirty-eight investigations were considered nonassessable. CONCLUSION: This study demonstrated the importance of revealing the difficulties and limitations for each technique and problems in interpreting results, which are crucial for therapeutic decisions. Moreover, it led to the formulation of guidelines that are applicable to all kinds of tumors and that contain the standardization of techniques, including the exact determination of the tumor cell content. Finally, the group has developed a common terminology for molecular-genetic results. 相似文献
62.
63.
De Bernardi B Mosseri V Rubie H Castel V Foot A Ladenstein R Laureys G Beck-Popovic M de Lacerda AF Pearson AD De Kraker J Ambros PF de Rycke Y Conte M Bruzzi P Michon J;SIOP Europe Neuroblastoma Group 《British journal of cancer》2008,99(7):1027-1033
Main objective of this study was to confirm that surgery alone is an effective and safe treatment for localised resectable neuroblastoma except stage 2 with amplified MYCN gene (MYCNA). Of 427 eligible stages 1-2 patients, 411 had normal MYCN and 16 had MYCNA. Of the 288 stage 1 patients with normal MYCN, 1 died of complications and 16 relapsed, 2 of whom died; 5-year relapse-free survival (RFS) and overall survival (OS) rates were 94.3% (95% confidence interval (CI): 91.6-97) and 98.9% (95% CI: 97.7-100), respectively. Of the 123 stage 2 patients with normal MYCN, 1 died of sepsis and 22 relapsed, 8 of whom died (RFS 82.8%, 95% CI: 76.2-89.5; OS 93.2%, 95% CI: 88.7-97.8). In stage 2, OS and RFS were worse for patients with elevated LDH and unfavourable histopathology. Of 16 children with MYCNA, 7 were stage 1 (5 relapses and 4 deaths) and 9 were stage 2 (3 relapses and 2 deaths) patients. In conclusion, surgery alone yielded excellent OS for both stage 1 and 2 neuroblastoma without MYCNA, although stage 2 patients with unfavourable histopathology and elevated LDH suffered a high number of relapses. Both stage 1 and 2 patients with MYCNA were at greater risk of relapse. 相似文献
64.
De Giorgi U Rosti G Slavin S Yaniv I Harousseau JL Ladenstein R Demirer T Dini G;European Group for Blood Marrow Transplantation Solid Tumours Paediatric Disease Working Parties 《British journal of cancer》2005,93(4):412-417
We reviewed the European Group for Blood and Marrow Transplantation (EBMT) experience with salvage high-dose chemotherapy (HDC) in paediatric patients with extragonadal germ-cell tumour (GCT). A total of 23 children with extragonadal GCT, median age 12 years (range 1-20), were treated with salvage HDC with haematopoietic progenitor cell support. The GCT primary location was intracranial site in nine cases, sacrococcyx in eight, retroperitoneum in four, and mediastinum in two. In all, 22 patients had a nongerminomatous GCT and one germinoma. Nine patients received HDC in first- and 14 in second- or third-relapse situation. No toxic deaths occurred. Overall, 16 of 23 patients (70%) achieved a complete remission. With a median follow-up of 66 months (range 31-173 months), 10 (43%) are continuously disease-free. Of six patients who had a disease recurrence after HDC, one achieved a disease-free status with surgical resection followed by chemotherapy and radiotherapy. In total, 11 patients (48%) are currently disease-free. Eight of 14 patients (57%) with extracranial primary and three of nine patients (33%) with intracranial primary GCT are currently disease-free. HDC induced impressive long-term remissions as salvage treatment in children with extragonadal extracranial GCTs. Salvage HDC should be investigated in prospective trials in these patients. 相似文献
65.
Moroz V Machin D Faldum A Hero B Iehara T Mosseri V Ladenstein R De Bernardi B Rubie H Berthold F Matthay KK Monclair T Ambros PF Pearson AD Cohn SL London WB 《European journal of cancer (Oxford, England : 1990)》2011,47(4):561-571